Nasdaq

First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF ...

Exarafenib was well-tolerated at substantial monotherapy exposures; only 3% (n=2/60) of patients discontinued therapy due to treatment-related adverse events Breadth of responses observed across tumor ...
ascopubs.org

Adjuvant Dose-Dense Chemotherapy in Hormone Receptor–Positive Breast Cancer

Melanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study In light of evolving evidence that some patients with node-positive estrogen receptor–positive ...
Nasdaq

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without any dose reductions or treatment ...
Business Wire

Gate Neurosciences Announces Positive Topline Human EEG Biomarker Results Demonstrating Dose-Dependent Target Activation in Phase 1 Study of Apimostinel

INDIANAPOLIS--(BUSINESS WIRE)--Gate Neurosciences, a clinical-stage biotechnology company using precision medicine approaches to develop next-generation neuroscience therapies, today announced ...